Preview

Остеопороз и остеопатии

Расширенный поиск

ИЗУЧЕНИЕ ПЕРЕНОСИМОСТИ АЛЕНДРОНАТА 70 МГ (ФОСАМАКС 70 МГ ОДИН РАЗ В НЕДЕЛЮ) И ПРИЧИНОТМЕНЫ ЛЕЧЕНИЯ У БОЛЬНЫХ ПОСТМЕНОПАУЗАЛЬНЫМОСТЕОПОРОЗОМ В УСЛОВИЯХ РЕАЛЬНОЙ КЛИНИЧЕСКОЙПРАКТИКИ

https://doi.org/10.14341/osteo2007331-35

Полный текст:

Аннотация

Проведено проспективное, открытое неконтролируемое исследование переносимости алендроната 70 мг в неделю и причин отмены лечения в условиях реальной клинической практики. Работа основана на результатах годичного наблюдения 427 пациенток (67+8,2 года) с установленным диагнозом постменопаузального остеопороза, которым было назначено лечение алендронатом 70 мг в неделю.
Наряду с остеопорозом, 64% исследуемых имели в анамнезе хронические заболевания ЖКТ, а 36% пациенток помимо алендроната получали многочисленные другие препараты.
В течение года наблюдения около 30% пациенток прекратили принимать алендронат. Наиболее часто отмена лечения происходила (% исследуемых; % причин) по финансовым причинам (20%; 68%), а также вследствие обострений хронических заболеваний ЖКТ (9%; 29,6%). Связь обострений с приемом алендроната не установлена. Отмечено 3 случая достоверной непереносимости алендроната 70 мг (0,7%; 2,3%). У пациентов, непрерывно продолжавших лечение в течение года, отмечена хорошая переносимость алендроната вне зависимости от наличия заболеваний ЖКТ (p=0,953); в 22% случаев наблюдались незначительные проявления диспепсии, связь которых с приемом алендроната не доказана.
При проведении терапии алендронатом 70 мг наиболее сложной клинической задачей является интерпретация нежелательных явлений. Необходимо дифференцировать побочные эффекты алендроната от проявлений фоновых заболеваний ЖКТ и негативных эффектов других медикаментов.

Список литературы

1. Дедов И.И., Рожинская Л.Я., Белая Ж.Е. «Роль и место бисфофонатов в профилактике и лечении остеопороза.10-летний опыт применения алендроната (Фосамакса). Обзор литературы». Остеопороз и остеопатии, 2005, № 1, стр. 20-30.

2. Древаль А.В., Марченкова Л.А., Крюкова И.В. и соавт. «Эффективность, переносимость и комплаентность алендронат натрия (70 мг 1 раз в неделю) при лечении постменопаузального остеопороза». Остеопороз и остеопатии 2006, № 2, стр 13-17.

3. Клинические рекомендации. Гастроэнтерология / под ред. В.Т. Ивашкина - М.: ГЭОТАР-Медиа 2006. - стр. 30-35.

4. Клинические рекомендации. Остеопороз. Диагностика, профилактика и лечение / под ред. Л.И. Беневоленской, О.М. Лесняк - М.: ГЭОТАР-Медиа, 2005. - стр. 66-72.

5. Aki S., Eskiyurt N., et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med J. 2003 Dec 30;44 (6):961-7

6. Amagase K., Hayashi S., Nishikawa K., et al. Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats. Dig Dis Sci. 2007 Aug;52 (8):1879-89. Epub 2007 Apr 5

7. Anastasilakis A.D., Goulis D.G., Kita M., Avramidis A. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. Hormones (Athens). 2007 Jul-Sep;6 (3):233-41.

8. Bartl R., Götte S., Hadji P., Hammerschmidt T. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment] Dtsch Med Wochenschr. 2006 Jun 2;131 (22):1257-62.

9. Bauer D.C., Black D., Ensrud K. et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000, 160: 517-25.

10. Blouin J., Dragomir A., Ste-Marie L.G., et al. Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002- 2004 among osteoporotic women. J Clin Endocrinol Metab. 2007 Mar; 92 (3):887-94.

11. Bonnick S,. Saag K.G., Kiel D.P., et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006 Jul; 91 (7):2631-7.

12. Briesacher B.A., Andrade S.E., Yood R.A., Kahler K.H. Consequences of poor compliance with bisphosphonates. Bone. 2007 Jul 18; [Epub ahead of print]

13. Briot K., Tremollieres F., Thomas T., Roux C.; How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine. 2007 Jan;74 (1):24-31.

14. Brookhart M.A., Avorn J., Katz J.N., et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med. 2007 Mar;120 (3):251-6.

15. Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006, 368:2005-2006

16. Cooper A., Drake J., Brankin E., et al. Treatment persistence with once-monthly ibandronate and patient support vs. once weekly alendronate: results from the PERSIST study. J Clin Practice, 2006, 60:896-905

17. Cramer J.A., Amonkar M.M., Hebborn A., Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005 Sep;21 (9):1453-60.

18. Cramer J.A., Lynch N.O., Gaudin A.F., et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 2006 Oct;28 (10):1686-94.

19. Cranney A., Guyatt G., Griffith L., Wells G., Tugwell P., Rosen C., et al. Summary of meta-analysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23: 570-8.

20. Cryer B., Bauer D.C. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002; 77: 1031-43.

21. Cryer B., Binkley N., Simonelli C. et al. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am О Geriatr Pharmacother, 2005, Sep; 3 (3): 127-36.

22. Cryer B., Miller P., Petruschke R.A. et al. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2005 Mar 1;21 (5):599-607.

23. Downey T.W., Foltz S.H., Boccuzzi S.J., et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J. 2006 Jun;99 (6):570-5.

24. Eisman J.A., Rizzoli R., et al. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2004 May;20 (5):699-705.

25. Emkey R.D., Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med, 2006, 119:S18-S24

26. Fardellone P., Gaudin A.F., Cotte F.E. Comparison of the persistence of daily and weekly bisphosphonates in female patients treated for osteoporosis. J Bone Miner Res, 2005, 20 (Suppl 1):S285-S286

27. Gold D.T., Alexander I.M., Ettinger M.P. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother. 2006 Jun;40 (6):1143-50.

28. Goldstein J.L., Eisen G.M., Lewis B., et al. Video capsule endoscopy to prospectively access small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol., 2005;3:133- 141.

29. Graham D.Y., Malaty H.M. Alendronate and naproxen are synergistic for development of gastric ulcers Arch Intern Med., 2001, Jan 8;161 (1):107-10.

30. Greenspan S., Field-Munves E., et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2002 Oct;77 (10):1044-52.

31. Heras Rincón I., Zubillaga Rodriguez I., et al. Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic recommendations. Med Oral Patol Oral Cir Bucal. 2007 Aug 1;12 (4):E267-71.

32. Ho A.Y., Kung A.W. Efficacy and tolerability of alendronate once weekly inAsian postmenopausal osteoporotic women. Ann Pharmacother. 2005 Sep;39 (9):1428-33.

33. ICSI Health Care Guidline: Diagnosis and Treatment of Osteoporosis, Fifth Edition, July 2006. www.icsi.org <http://www.icsi.org>.

34. Ideguchi H., Ohno S., Hattori H., Ishigatsubo Y. Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int, 2007, 18:1421-1427.

35. Iwamoto J., Takeda T., Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin. 2006 May;22 (5):919-28.

36. Khapra A.P., Rose S. Drug injury in the upper gastrointestinal tract: effects of alendronate. Gastrointest Endosc Clin N Am. 2006 Jan;16 (1):99-110.

37. Lanza F., Rack M.F., et al. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol. 1998 May;93 (5):753-7.

38. Lanza F., Schwartz H., et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol. 2000 Nov;95 (11):3112-7.

39. Lanza F., Sahba B., et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol. 2002 Jan;97 (1):58-64.

40. Lekkerkerker F., Kanis J.A., Alsayed N., et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int (2007) 18:1311-1317.

41. Marshall J.K. The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Saf. 2002 May;1 (1):71-8.

42. Marshall J.K., Thabane M., James C. Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronate. Dig Dis Sci., 2006, May;51 (5):864-8. Epub 2006 Apr 27.

43. Miller P.D., Woodson G., Licata A.A., et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther. 2000 Dec;22 (12):1433-42.

44. NICE Technology Appraisal 87 January 2005 Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. www.nice.org.uk <http://www.nice.org.uk>.

45. Penning-van Beest F.J., Goettsch W.G., Erkens J.A., Herings R.M. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006 Feb;28 (2):236-42. Penning-van Beest F.J., Erkens J.A., Olson M., Herings R.M. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2007 Sep 14; [Epub ahead of print]

46. Purcell P.M., Boyd I.W. «Bisphosphonates and osteonecrosis of the jaw.» Medical Journal of Australia, 2005, 182 (8), 417-8.

47. Ringe J.D., Christodoulakos G.E. Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin. 2007 Sep 19; [Epub ahead of print]

48. Rossini M., Bianchi G., Di Munno O., et al.; Treatment of Osteoporosis in clinical Practice (TOP) Study Group Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17 (6):914-21.

49. Sambrook P. Once weekly alendronate. Drugs Today (Barc), 2003 May;39 (5):339-46.

50. Sener G., Goren F.O., Ulusoy N.B., et al. Protective effect of melatonin and omeprazole against alendronat-induced gastric damage. Dig Dis Sci., 2005, Aug;50 (8):1506-12.

51. Sener G., Sehirli O., Cetinel S., et al. Protective effect of taurine against alendronate-induced gastric damage in rats. Fundam Clin Pharmacol.,2005,Feb;19 (1):93-100.

52. Simon J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002 Nov;24 (11):1871-86.

53. Simon L.S., Lanza F.L., et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum, 1998, Sep; 41 (9): 1591-602.

54. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. The Journal of Rheumatology, 1999, V6, S56.

55. Solomon D.H., Avorn J., Katz et al. Compliance with osteoporosis indications. Arch Intern Med,2005, 165:2414-2419

56. Unson C.G., Siccion E., Gaztambide J., et al. Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt). 2003 Dec;12 (10):1037-45.

57. Watts N., Freedholm D., Daifotis A. The clinical tolerability profile of alendronate. Int J Clin Pract Suppl. 1999 Apr;101:51-61.

58. Weiss M., Vered I., Foldes A.J., Cohen Y.C., Shamir-Elron Y., Ish-Shalom S.; Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res. 2005 Apr;17 (2):143-9.

59. Weycker D., Macarios D., Edelsberg J. et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int,2006, 17:1645-1652


Рецензия

Для цитирования:


., ., ., . ИЗУЧЕНИЕ ПЕРЕНОСИМОСТИ АЛЕНДРОНАТА 70 МГ (ФОСАМАКС 70 МГ ОДИН РАЗ В НЕДЕЛЮ) И ПРИЧИНОТМЕНЫ ЛЕЧЕНИЯ У БОЛЬНЫХ ПОСТМЕНОПАУЗАЛЬНЫМОСТЕОПОРОЗОМ В УСЛОВИЯХ РЕАЛЬНОЙ КЛИНИЧЕСКОЙПРАКТИКИ. Остеопороз и остеопатии. 2007;10(3):31-35. https://doi.org/10.14341/osteo2007331-35

For citation:


LYaLINA V.V., MYLOV N.M., DMITRIEVA E.G., KORVYaKOV E.L. IZUChENIE PERENOSIMOSTI ALENDRONATA 70 MG (FOSAMAKS 70 MG ODIN RAZ V NEDELYu) I PRIChINOTMENY LEChENIYa U BOL'NYKh POSTMENOPAUZAL'NYMOSTEOPOROZOM V USLOVIYaKh REAL'NOY KLINIChESKOYPRAKTIKI. Osteoporosis and Bone Diseases. 2007;10(3):31-35. (In Russ.) https://doi.org/10.14341/osteo2007331-35

Просмотров: 444


ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)